- Description
- Specifications
Catalog #: CYT-222
Description:
Granulocyte Macrophage Colony Stimulating Factor Mouse Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 125 amino acids and having a molecular mass of 14285.35 Dalton.
GM-CSF Mouse is purified by proprietary chromatographic techniques.
Synonyms:
CSF-2, MGI-1GM, GM-CSF, Pluripoietin-alpha, Molgramostin, Sargramostim.
Source:
Escherichia Coli.
Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Pro-Thr-Arg.
Purity:
Greater than 98.0% as determined by(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Solubility:
It is recommended to reconstitute the lyophilized Granulocyte Macrophage Colony Stimulating Factor in sterile 20mM AcOH (acetic Acid) not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
Formulation:
GM-CSF Mouse was lyophilized with no additives.
Stability:
Lyophilized Granulocyte Macrophage Colony Stimulating Factor although stable at room temperature for 3 weeks, should be stored desiccated below -18 °C. Upon reconstitution GM-CSF should be stored at 4 °C between 2-7 days and for future use below -18 °C.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
Activity:
The ED50 as determined by the dose-dependant stimulation of the proliferation of murine FDC-P1 cell line is < 0.2 ng/ml, corresponding to a Specific Activity of 5,000,000 IU/mg.
Physical Appearance:
Sterile Filtered White lyophilized (freeze-dried) powder.
Protein Content:
GM-CSF quantitation was carried out by two independent methods
1. UV spectroscopy at 280 nm using the absorbency value of 0.765 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a calibrated solution of GM-CSF as a Reference Standard.
Usage:
Denovo Biotechnology's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
References:
1.Title:Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.
Publication: Mol Ther. 2005 Dec;12(6):1197-205. Epub 2005 Aug 22. PMID: 16112909
Link: http://www.nature.com/mt/journal/v12/n6/full/mt20051405a.html
Applications: The Mouse GM-CSF used for 2 purposes:
1. As an adjuvant for DNA vaccine which included seven plasmids encoding nine HIV-1 proteins. The mice were injected with the DNA vaccine together with recombinant mouse GM-CSF. 2. Used in Elisa.
2.Title: Neospora caninum: cloning and expression of a gene coding for cytokine-inducing profilin.
Publication: Exp Parasitol. 2010 Aug;125(4):357-62. Epub 2010 Mar 6. PMID: 20211619
Link: http://www.sciencedirect.com/science/article/pii/S001448941000086X
Applications: Used for immunoblotting
3.Title: Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: Antimicrob Agents Chemother. 2008 February; 52(2): 716–718.
Published online 2007 November 5
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2224773/?tool=pmcentrez
Applications: GM-CSF as tested a therapeutic potential in a murine model of pulmonary aspergillosis. In summary, this pilot study indicates that GM-CSF administered intranasally may be a novel therapeutic approach for the prevention or treatment of pulmonary fungal infections and may augment the efficacies of antifungal agents.
GM-CSF was given intranasal.
4.Title: Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
Publication: The Journal of Immunology February 1, 2009 vol. 182 no. 3 1667-1673
Link:
http://www.jimmunol.org/content/182/3/1667.full
5.Title:Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer.
Publication:Article first published online: 21 JUN 2007 DOI:10.1111/j.1365-3083.2007.01945.x
Scandinavian Journal of Immunology Volume 66, Issue 1, pages 43–51, July 2007
Link:http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2007.01945.x/full
6.Title:Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: First published November 2007, doi: 10.1128/?AAC.00760-07 Antimicrob. Agents Chemother. February 2008 vol. 52 no. 2 716-718
Link:http://aac.asm.org/content/52/2/716.full
